Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1 Carcinoma, Non-Small-Cell Lung 1 BRAF V600E Mutation 1

Interventions

pembrolizumab 115 Carboplatin 103 Pemetrexed 90 Cisplatin 58 Paclitaxel 47 osimertinib 40 Drug Therapy 40 Nivolumab 39 Docetaxel 35 Specimen Handling 33 Magnetic Resonance Spectroscopy 28 Bevacizumab 26 durvalumab 23 Gemcitabine 22 cemiplimab 21 Radiotherapy 20 130-nm albumin-bound paclitaxel 20 Radiosurgery 19 tislelizumab 18 atezolizumab 17 aflutinib 15 Cetuximab 15 Immunotherapy 14 Immune Checkpoint Inhibitors 14 Platinum Compounds 13 Ipilimumab 13 Biopsy 12 Standard of Care 11 Surgical Procedures, Operative 10 Injections 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma, Non-Small-Cell Lung × Cobicistat × Clear all

NCT05748093 2024-08-09

OSIBOOST 2

Maastricht University Medical Center

Phase 4 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡